EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunoevaluation of a Prokaryotic-Expressed Goose Circovirus Capsid Subunit Vaccine

Wenchang Xue, Chao Wang, Zhanxin Yao, Jialong Chen, Jipei Zhang, Jidang Chen

Microorganisms · 29.05.2026 · 14 (6) · 1227

DOI: 10.3390/microorganisms14061227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microorganisms, online erschienen am 29.05.2026. Verfasst von Wenchang Xue und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Animal Science and Technology, Foshan University, Foshan 528225, China. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Department of Science and Technology of Guangdong Province, Young Scientists Fund of the National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To address the lack of a commercially available vaccine for goose circovirus (GoCV), we developed and evaluated a prokaryotically expressed subunit vaccine targeting the viral capsid (Cap) protein. A truncated Cap protein (GoCV-ΔCap) was expressed in Escherichia coli (E. coli) and formulated with aluminum hydroxide as a subunit vaccine (GoCVsubvac). Goslings were primed intramuscularly (i.m.) with high (75 µg) or low (15 µg) doses GoCVsubvac, followed by a boost 14 days later. At 14 days post-boost, goslings were challenged with GoCV and were administered a bivalent inactivated vaccine against Newcastle disease virus (NDV) and H9-subtype Avian influenza virus (AIV). Using our established gosling pathogenicity model, vaccine efficacy was evaluated via body weight, lesions, viral load, antibody titers, cytokine responses, and interference with NDV/AIV immunity. Results demonstrated that the GoCV-ΔCap vaccine, especially the high-dose formulation, provided effective immunoprotection. It elicited robust humoral and cellular immune responses, reduced lymphoid pathology, and decreased the viral detection rate in lymphoid tissues from 100% (5/5) in infected controls to 40% (2/5). Importantly, it alleviated GoCV-induced immunosuppression and preserved the immunogenicity of co-administered vaccines. This novel subunit vaccine is a promising candidate for controlling GoCV disease (GoCVD).

Schlagwörter

Stichwörter der Autor:innen

capsid proteingoose circovirusimmunoevaluationsubunit vaccine

Autor:innen und Institutionen

  • School of Animal Science and Technology, Foshan University, Foshan 528225, China.
  • College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Taian 271018, China.
  • Agricultural Teaching and Research Bases, Foshan University, Foshan 528225, China.

Förderung

  • National Natural Science Foundation of China
  • Department of Science and Technology of Guangdong Province
  • Young Scientists Fund of the National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province, China
  • Rural Revitalization Strategy Special Foundation of Guangdong Province
  • Science and Technology Innovation Program of Gaoming District, Foshan City
  • Collaboration Project with WANMUZHOU Biotechnology Limited Company

Zitieren

APA

Xue, W., Wang, C., Yao, Z., Chen, J., Zhang, J., & Chen, J. (2026). Immunoevaluation of a Prokaryotic-Expressed Goose Circovirus Capsid Subunit Vaccine. Microorganisms, 14(6), 1227. https://doi.org/10.3390/microorganisms14061227

Vancouver

Xue W, Wang C, Yao Z, Chen J, Zhang J, Chen J. Immunoevaluation of a Prokaryotic-Expressed Goose Circovirus Capsid Subunit Vaccine. Microorganisms. 2026;14(6):1227. doi:10.3390/microorganisms14061227

BibTeX
@article{Xue2026,
  author = {Xue, Wenchang and Wang, Chao and Yao, Zhanxin and Chen, Jialong and Zhang, Jipei and Chen, Jidang},
  title = {Immunoevaluation of a Prokaryotic-Expressed Goose Circovirus Capsid Subunit Vaccine},
  journal = {Microorganisms},
  year = {2026},
  volume = {14},
  number = {6},
  pages = {1227},
  doi = {10.3390/microorganisms14061227}
}
Kostenlos starten →